phrykt

Coherus Oncology, Inc. (CHRS): who owns it and who trades it

As of Nov 16, 2026, no open-market insider purchases or sales of CHRS were reported in the last 12 months. 3 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Coherus Oncology

From the latest filings

Overall: more buying than selling. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns CHRS

147 funds and institutions reported CHRS shares worth $100M at the end of Q2 2026, about 46% of the company. The largest holder is Timothy G. Youngquist 2020 Irrevocable Trust with 8.5%.

Funds and institutions (13F) 46%Everyone else 54%

10 largest owners, by share of the company

Timothy G. Youngquist 2020 Irrevocable Trust8.5%
BlackRock, Inc.7.8%
Vanguard Capital Management LLC3.9%
Geode Capital Management, LLC2.4%
Samsara Biocapital, LLC2.2%
Kohlberg Kravis Roberts & Co. L.P.2.0%
State Street Corp1.5%
Two Sigma Investments, LP1.5%
CM Management, LLC1.4%
C WorldWide Group Holding A/S1.3%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Timothy G. Youngquist 2020 Irrevocable Trust13.05M8.46%$18.3M–
BlackRock, Inc.12.00M7.78%$16.8M+16%
Vanguard Capital Management LLC5.95M3.86%$8.3M+9%
Geode Capital Management, LLC3.69M2.39%$5.2M+18%
Samsara Biocapital, LLC3.43M2.22%$4.8MNo change
Kohlberg Kravis Roberts & Co. L.P.3.04M1.97%$4.2MNo change
State Street Corp2.38M1.54%$3.3M+2%
Two Sigma Investments, LP2.26M1.46%$3.2M-2%
CM Management, LLC2.10M1.36%$2.9MNo change
C WorldWide Group Holding A/S1.93M1.25%$2.7MNo change
Alyeska Investment Group, L.P.1.73M1.12%$2.4M-23%
Hudson Bay Capital Management LP1.69M1.10%$2.4M-1%
AQR Capital Management LLC1.33M0.86%$1.9M+10%
Charles Schwab Investment Management Inc1.23M0.80%$1.7M+6%
Sixth Street Partners Management Company, L.P.1.23M0.80%$1.7M–
Panagora Asset Management Inc1.14M0.74%$1.6M-22%
Northern Trust Corp1.13M0.73%$1.6M+24%
Vanguard Fiduciary Trust Co1.02M0.66%$1.4M+7%
Nomura Asset Management International Inc.899,9990.58%$1.3MNo change
Vanguard Portfolio Management LLC883,4540.57%$1.2M+46%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

No CHRS insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

CHRS short interest

Moderate short interest. 8.2% of CHRS shares are sold short: about 1 share in 12. Over the last 12 reports the number of shares short went down 55%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 12.71M CHRS shares were sold short, 8.2% of the shares outstanding, up 2.1% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

8.23%May 15Oct 3019.7%

Days to cover

8.2May 15Oct 3060.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202612.71M8.23%+2%1.55M8.2
Oct 15, 202612.45M8.06%-47%1.58M7.9
Sep 30, 202623.34M15.11%+2%1.86M12.5
Sep 15, 202622.85M14.79%-4%697,55332.8
Aug 31, 202623.92M15.48%-0%1.42M16.8
Aug 14, 202624.00M15.53%-2%1.22M19.7
Jul 31, 202624.53M15.88%+3%457,68453.6
Jul 15, 202623.89M15.49%-8%980,71424.4
Jun 30, 202625.98M16.84%+1%1.19M21.9
Jun 15, 202625.64M16.62%-8%767,40233.4
May 29, 202627.87M18.07%-1%1.18M23.7
May 15, 202628.11M18.22%+1%1.64M17.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Coherus Oncology company events

Coherus Oncology filed 14 reports on Form 8-K in the last 12 months, 1 of them about an important change (auditor). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Oct 29, 2026AnnouncementThe Company announced interim clinical data from the TREGCHECK™ development program evaluating tagmokitug, its investigational cytolytic CCR8 antibody, in combination with toripalimab, with or without chemotherapy. Filing
  3. Aug 28, 2026AnnouncementCoherus Oncology, Inc. entered into a sales agreement with Leerink Partners LLC, pursuant to which the Company may offer and sell, from time to time, through or to the Agent, acting as agent or principal, shares of the Company’s common stock, par value $0.0001 per share, having an aggregate… Filing
  4. Aug 17, 2026AnnouncementThe Company announced a special dividend of CVRs. Filing
  5. Aug 17, 2026AgreementCoherus Oncology, Inc., together with certain wholly owned subsidiaries of the Company (collectively with the Company, the “Borrowers”), entered into a Loan and Security Agreement with Innovatus Life Sciences Lending Fund I, LP, as collateral agent (in such capacity, the “Collateral Agent”), and… Filing
  6. Aug 5, 2026ResultsReleased financial results. Filing
  7. Jun 15, 2026AuditorChanges in Registrant’s Certifying Accountant. Filing
  8. Jun 1, 2026VoteReported shareholder vote results. Filing
  9. May 11, 2026ResultsReleased financial results. Filing
  10. Mar 9, 2026ResultsReleased financial results. Filing
  11. Feb 17, 2026AnnouncementCoherus Oncology, Inc. entered into an underwriting agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Oppenheimer & Co. Inc. as representatives of the several underwriters named therein, pursuant to which the Company agreed to issue and sell an aggregate of 28,600,000 shares of… Filing
  12. Feb 4, 2026AnnouncementCoherus Oncology, Inc. announced a clinical supply agreement with Janssen Research & Development, LLC, to evaluate tagmokitug (CHS-114), the Company’s investigational anti-CCR8 cytolytic monoclonal antibody, in combination with pasritamig, a T-cell engaging bispecific antibody, in a Phase 1b… Filing
  13. Jan 23, 2026AnnouncementCoherus Oncology, Inc. filed a prospectus supplement relating to its Sales Agreement, dated November 8, 2022, by and between the Company and Cowen and Company LLC, as amended by the Amendment No. 1 to Sales Agreement, dated May 15, 2023 and Amendment No. 2 to Sales Agreement, dated September 11… Filing
  14. Jan 13, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Coherus Oncology financials

Famous investors that hold CHRS

3 of the 50 well-known investors we track reported holding CHRS in their latest 13F filing. The largest position is Jim Simons's, worth $1.1M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026941,828$1.1M0.0%+67%
Ken Griffin · Citadel AdvisorsQ3 2026282,191$341K0.0%+570%
Israel Englander · Millennium ManagementQ3 2026196,342$107K0.0%+846%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Coherus Oncology, Inc. (CHRS) stock

Who owns the most CHRS stock?

The largest reported owner of Coherus Oncology, Inc. (CHRS) is Timothy G. Youngquist 2020 Irrevocable Trust, with 8.5% of the company. In total, 147 funds and institutions reported holding CHRS at the end of Q2 2026, together about 46% of the shares. See the largest owners.

Are CHRS insiders buying or selling?

No CHRS insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in CHRS?

As of Oct 30, 2026, 12.71M CHRS shares were sold short, 8.2% of the shares outstanding, up 2.1% from the report before. At the average daily volume of 1.55M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Which famous investors hold CHRS?

3 of the 50 well-known investors we track reported CHRS in their latest 13F filing, including Jim Simons, Ken Griffin, Israel Englander. The largest position is worth $1.1M. See all holders.

Executive pay

Coherus Oncology's chief executive was paid a total of $2.7M for the year ended Dec 31, 2025, down 43% from $4.8M the year before. In the last 12 months, Coherus Oncology's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$2.7MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$2.8MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.2MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.